Over the past five years, through innovative partner collaboration, the global HIV community achieved historic milestones in HIV treatment optimization. Today over 90 percent of adults on first-line treatment are expected to be on dolutegravir (DTG)-based regimens, DTG is now available for the youngest children, and once-out-of-reach protease inhibitors are available at affordable prices. However, to reach critical global targets, the global HIV community must accelerate efforts to facilitate the paradigm shift toward enabling greater patient choice and prepare for the exciting and evolving treatment pipeline consisting of long-acting products. This satellite session will bring together key stakeholders to reflect on the innovative market interventions that have transformed the HIV treatment landscape in low- and middle-income countries and how these learnings will shape future initiatives. The session will challenge key stakeholders, including suppliers, national programs, and donors, to chart the future course of HIV treatment optimization and catalyze the rapid and appropriate introduction of next-generation innovations, including long-acting products.

• Presentations
• Session recording (English)